These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20078617)

  • 21. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
    Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.
    Aklillu E; Mugusi S; Ngaimisi E; Hoffmann MM; König S; Ziesenitz V; Mikus G; Haefeli WE; Weiss J
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1139-45. PubMed ID: 21630030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
    Gutiérrez F; Padilla S; Navarro A; Masiá M; Hernández I; Ramos J; Esteban A; Martin-Hidalgo A
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):594-600. PubMed ID: 12902803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
    Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
    AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
    Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
    Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
    Delgado O; Riera M; Murillas J; Ventayol P
    Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):182-3. PubMed ID: 18358222
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
    Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method.
    Yoshida K; Takano J; Ishizu Y; Lezhava A; Ieiri I; Maeda K; Hayashizaki Y; Sugiyama Y
    AAPS J; 2013 Apr; 15(2):618-22. PubMed ID: 23471819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.
    Seminari E; Gentilini G; Galli L; Hasson H; Danise A; Carini E; Dorigatti F; Soldarini A; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2005 Oct; 56(4):790-2. PubMed ID: 16143711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability in plasma rifampicin concentrations and role of
    Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
    Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of
    Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B
    Pharmacogenomics; 2019 May; 20(7):517-527. PubMed ID: 31124411
    [No Abstract]   [Full Text] [Related]  

  • 39. Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
    Notari S; Sergi M; Montesano C; Ivanovic J; Narciso P; Pucillo LP; Ascenzi P
    IUBMB Life; 2012 May; 64(5):443-9. PubMed ID: 22473795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
    Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
    AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.